Showing 2061-2070 of 2526 results for "".
- Google Commits $150M to COVID-19 Vaccine Education, Partnering With One Medical to Open Vaccination Siteshttps://modernod.com/news/google-commits-150m-to-covid-19-vaccine-education-partnering-with-one-medical-to-open-vaccination-sites/2478801/Google is committing $150 million to promote COVID-19 vaccine education and equitable distribution to underserved communities, the tech giant announced Monday, as
- Study: Implandata’s Eyemate System Protects Glaucoma Patients–Even During Lockdownhttps://modernod.com/news/study-implandatas-eyemate-system-protects-glaucoma-patients-even-during-lockdown/2478767/Patients with glaucoma are at high risk of losing their eyesight if their disease progresses undetected and essential therapy adjustments are delayed. On the other hand, these typically elderly, vulnerable individuals are often hampered in seeing their doctor for office visits, particularly durin
- GenSight Biologics Announces Publication of Results from Lumevoq RESCUE Phase 3 Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-rescue-phase-3-trial/2478755/GenSight Biologics announced that Ophthalmology has published results from the RESCUE pivotal phase 3 clinical trial of Lumevoq gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects. The paper, published in the January issue under the title, “Efficacy and safety
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-24-months-in-phase-2b-study/2478753/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 24-month interim analysis of the ongoing 36-month phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. Administered
- US IDE Trial Results for Glaukos’ iStent infinite Show Reduction in IOPhttps://modernod.com/news/us-ide-trial-results-for-glaukos-istent-infinite-show-reduction-in-iop/2478754/Glaukos announced that 12-month U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent infinite Trabecular Micro-Bypass System achieved a substantial reduction in mean diurnal IOP in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy
- EMA Receives Conditional Marketing Request for AstraZeneca’s COVID-19 Vaccinehttps://modernod.com/news/ema-receives-conditional-marketing-request-for-astrazenecas-covid-19-vaccine/2478752/The European Medicines Agency announced Tuesday that it received an application for conditional marketing authorization of AstraZeneca and the University of Oxford’s COVID-19 vaccine AZD1222. The regulator noted that the vaccine will be reviewed under an accelerated timeline with an opinion
- Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-first-patients-enrolled-in-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478744/Clearside Biomedical announced that the first patients have been enrolled in its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). Clinical sites, all based in the United States, are activated and curr
- Alcon Commercially Launches AcrySof IQ Vivity Extended Depth of Focus IOL in UShttps://modernod.com/news/alcon-launches-acrysof-iq-vivity-extended-depth-of-focus-iol-in-us/2478731/Alcon has commercially launched the AcrySof IQ Vivity IOL, which the company describes as the first and only non-diffractive extended depth of focus IOL in the United States. Vivity is a first-of-its-kind, non-diffractive extended depth of focus IOL with Alcon’s proprietary non-diffractiv
- Birmingham Research Paves the Way for New Anti-Fibrotic Therapy for Glaucomahttps://modernod.com/news/birmingham-research-paves-the-way-for-new-anti-fibrotic-therapy-for-glaucoma/2478727/Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB, could play a key role in treating open angle glaucoma (OAG). The research, reported in
- Study: Hospitals At or Near Full COVID-19 ICU Capacity Increase by 90% Over Past Few Monthshttps://modernod.com/news/study-hospitals-at-or-near-full-covid-19-icu-capacity-increase-by-90-over-past-few-months/2478722/A new study found a 90% increase in hospitals reaching intensive care unit (ICU) capacity from July through December, with rural hospitals facing the biggest capacity issues, according to a FierceHealthcare